Table 1 Baseline clinical characteristics of study subjects
From: A randomized trial of transdermal and oral estrogen therapy in adolescent girls with hypogonadism
Group | Age (y) | Height SDS | BMI (kg/m2) | Diagnosis | Years on GH | FSH | LH | |
|---|---|---|---|---|---|---|---|---|
OCEE | 15 | -1.065 | 15.3 | Kallmann syndrome | - | 2 | 0.47 | |
OCEE | 14.27 | -3.835 | 13.2 | BMT | - | 194 | 86 | |
OCEE | 12.98 | -1.211 | 26.2 | BMT | - | 117 | 51 | |
OCEE | 15.21 | -1.678 | 40.2 | Turner syndrome | - | 55 | 29 | |
OCEE | 13.31 | -2.922 | 19.0 | Turner syndrome | 3.5 | 58 | 13 | |
OCEE | 14.36 | -1.577 | 19.3 | Panhypopituitarism | 5 | 0.027 | 0.009 | |
OCEE | 12.9 | -2.997 | 22.2 | Turner syndrome | 1.7 | 65 | 16 | |
OCEE | 12.56 | -1.866 | 20.1 | Turner syndrome | 2.3 | 197 | 15 | |
Mean ± SE | 13.8 ± 0.4 | -2.14 ± 0.35 | 22 ± 3 | 3.1 ± 0.7 | 86 ± 27.2 | 26 ± 10.3 | ||
OBE | 16.11 | 0.061 | 18.5 | Kallmann syndrome | - | 0.656 | 0.041 | |
OBE | 13.62 | -3.141 | 18.2 | AI | - | 144 | 14 | |
OBE | 14.15 | -1.532 | 20.0 | Turner syndrome | 9.4 | 46 | 12 | |
OBE | 16.05 | -4.203 | 17.0 | Turner syndrome | 0.8 | 117 | 26 | |
OBE | 14.3 | -2.723 | 20.5 | Turner syndrome | 3.7 | 40 | 8.5 | |
OBE | 15.32 | -4.486 | 19.4 | Turner syndrome | 1.7 | 70 | 16 | |
OBE | 12.02 | -1.608 | 19.1 | Turner syndrome | 0.7 | 76 | 13 | |
Mean ± SE | 14.5 ± 0.6 | -2.52 ± 0.61 | 19 ± 0.4 | 3.3 ± 1.6 | 71 ± 18.3 | 13 ± 3 | ||
TBE | 15.32 | 0.291 | 16.6 | Kallmann syndrome | - | 1.5 | 0.15 | |
TBE | 13.75 | -2.637 | 13.0 | Delayed puberty | - | 3 | 0.571 | |
TBE | 12.5 | -3.03 | 19.1 | Turner syndrome | 5 | 118 | 24 | |
TBE | 15.43 | -3.079 | 18.5 | Turner syndrome | 0.8 | 114 | 17 | |
TBE | 14.16 | -3.742 | 19.5 | Turner syndrome | 7.3 | 144 | 26 | |
Mean ± SE | 14.2 ± 0.5 | -2.44 ± 0.71 | 17.4 ± 1.2 | 4.4 ± 1.9 | 76 ± 30.6 | 14 ± 5.6 |